Yehuda Baruch - OWC Pharmaceutical Chief Science Officer
| OWCP Stock | USD 0.0001 0.00 0.00% |
Executive
Dr. Yehuda Baruch is Chief Medical and Regulatory Officer of the Company. Prior to his appointment, Dr. Baruch served as Director of Research and Regulatory Affairs of the Registrant whollyowned Israeli subsidiary, One World Cannabis Ltd. since January 2015. Prior to joining the Registrant, Dr. Baruch served as Head of the Israeli Ministry of Health Medical Marijuana Program from 2003 through 2013, directing its efforts on regulation, chaired the indication committee, secured Helsinki Approvals for medical research, and managed regulation of patient licensing and dosage. Dr. Baruch has extensive experience in researching medical cannabis, most notably for its effect on PTSD. From 2004 until 2014, Dr. Baruch also served as CEO of Abarbanel Mental Health Center in Bat Yam, Israel, prior to which, he was the director of Israel Ministry of Health medical management division, and director general of Beer Yakov Mental Health Center. He has taught at BenGurion University of the Negev and Tel Aviv University Sackler School of Medicine. As Colonel in the Israeli Defense Force Medical Corporationration, Dr. Baruch was the director of the Israeli field hospital in India following the 2001 earthquake and was the director of the joint USAIsrael Mental Health Team operation in Sri Lanka following the 2004 tsunami. Dr. Baruch was the director of the Health Administration Division in the Israel Ministry of Health for five years from 1999 to 2004 and for the past 6 years was the director of Abarbanel Mental Health Center and lecturer at Ben Gurion and Bar Ilan Universities since 2018.
| Age | 66 |
| Tenure | 6 years |
| Phone | 972 72 260 8004 |
| Web | https://www.owcpharma.com |
OWC Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of (0.6448) % which means that it has lost $0.6448 on every $100 spent on assets. This is way below average. OWC Pharmaceutical's management efficiency ratios could be used to measure how well OWC Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Thomas Rowland | ANI Pharmaceuticals | 57 | |
| Ori Gutwerg | ANI Pharmaceuticals | 49 | |
| Lance Blundell | cbdMD Inc | 53 | |
| Krista Davis | ANI Pharmaceuticals | 50 | |
| Christopher MD | Collegium Pharmaceutical | N/A | |
| Alycia Torres | Biofrontera | N/A | |
| Mary MD | ANI Pharmaceuticals | N/A | |
| David Johnson | cbdMD Inc | 54 | |
| Omri Batzir | INC Research Holdings | N/A | |
| Jessica Novak | Evolus Inc | N/A | |
| Samantha Widdicombe | Biofrontera | N/A | |
| Bart Dunn | Collegium Pharmaceutical | N/A | |
| James Marken | ANI Pharmaceuticals | 61 | |
| Zeb Booker | cbdMD Inc | N/A | |
| Bradley Whitford | cbdMD Inc | 43 | |
| Jeffrey Plumer | Evolus Inc | N/A | |
| Chad Gassert | ANI Pharmaceuticals | 48 | |
| Christopher Mutz | ANI Pharmaceuticals | 53 | |
| BA MA | Akanda Corp | 74 | |
| Nareg Sagherian | Evolus Inc | N/A | |
| MD FAAFP | Collegium Pharmaceutical | 63 | |
Management Performance
| Return On Asset | -0.64 |
OWC Pharmaceutical Leadership Team
Elected by the shareholders, the OWC Pharmaceutical's board of directors comprises two types of representatives: OWC Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OWC. The board's role is to monitor OWC Pharmaceutical's management team and ensure that shareholders' interests are well served. OWC Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OWC Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ziv Turner, Chief Officer | ||
| Pr Ramot, Consultant | ||
| Oron DVM, Chief Officer | ||
| Alon Sinai, Chief Officer | ||
| Yehuda Baruch, Chief Science Officer | ||
| Shmuel DeSaban, CFO Sec |
OWC Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is OWC Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.64 | |||
| Current Valuation | 49.75 K | |||
| Shares Outstanding | 497.5 M | |||
| Shares Owned By Insiders | 11.15 % | |||
| Price To Earning | (12.76) X | |||
| Price To Book | 42.29 X | |||
| EBITDA | (10.25 M) | |||
| Net Income | (10.26 M) | |||
| Cash And Equivalents | 1.47 M | |||
| Cash Per Share | 0.01 X |
Pair Trading with OWC Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OWC Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OWC Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to OWC Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OWC Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OWC Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OWC Pharmaceutical Research to buy it.
The correlation of OWC Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OWC Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OWC Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OWC Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for OWC Pink Sheet Analysis
When running OWC Pharmaceutical's price analysis, check to measure OWC Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OWC Pharmaceutical is operating at the current time. Most of OWC Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of OWC Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OWC Pharmaceutical's price. Additionally, you may evaluate how the addition of OWC Pharmaceutical to your portfolios can decrease your overall portfolio volatility.